CHEK2 and cyclic hematopoiesis: This mechanism explains why individuals with ATM, CHEK2, and other HRR gene variants associated with hereditary breast and ovarian cancer syndromes possess a higher incidence of CH and resulting t-MNs with exposure to cancer-directed therapies.